S.BIOMEDICS Cell Therapy for Parkinson’s Disease Shows Positive Data from Its Phase 1/2a Clinical Trial
Seoul, South Korea – 21/07/2025 – (SeaPRwire) – S.BIOMEDICS announced encouraging one-year post-transplant results from Phase 1/2a clinical trial evaluating A9-DPC cell therapy for Parkinson’s disease. The data demonstrate a favorable safety and efficacy profile of A9-DPC in 12 participants at 12 months compared to baseline. Participants were divided equally into a low-dose group (3.15…